Drugs / Synchrotope TA2M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00023647 | Jul 2000 → Apr 2002 | cutaneous melanoma | Mannkind Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synchrotope TA2M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00023647 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00023647 ↗ |
| Modality | Vaccine | “intranodal Synchrotope TA2M plasmid DNA vaccine” NCT00023647 ↗ |